Literature DB >> 3072141

Guide to drug dosage in hepatic disease.

N M Bass1, R L Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3072141     DOI： 10.2165/00003088-198815060-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  161 in total

1.  Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction.

Authors:  M T Pasko; T R Beam; J A Spooner; D S Camara
Journal:  J Antimicrob Chemother       Date:  1985-03       Impact factor: 5.790

2.  Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver.

Authors:  P J Pentikäinen; P J Neuvonen; K G Jostell
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

3.  Chlordiazepoxide and oxazepam disposition in cirrhosis.

Authors:  E M Sellers; D J Greenblatt; H G Giles; C A Naranjo; H Kaplan; S M MacLeod
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

4.  Heparin elimination in patients with liver cirrhosis.

Authors:  A N Teien
Journal:  Thromb Haemost       Date:  1977-10-31       Impact factor: 5.249

5.  Triamterene kinetics and dynamics in cirrhosis.

Authors:  J P Villeneuve; F Rocheleau; G Raymond
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

6.  Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin.

Authors:  R L Williams; W L Schary; T F Blaschke; P J Meffin; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

7.  Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure).

Authors:  S Ward; E A Neill
Journal:  Br J Anaesth       Date:  1983-12       Impact factor: 9.166

8.  Furosemide disposition in cirrhosis.

Authors:  R K Verbeeck; R V Patwardhan; J P Villeneuve; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

9.  Fazadinium pharmacokinetics in patients with liver disease.

Authors:  P Duvaldestin; J Saada; D Henzel; G Saumon
Journal:  Br J Anaesth       Date:  1980-08       Impact factor: 9.166

10.  Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.

Authors:  K M Kessler; W C Humphries; M Black; J F Spann
Journal:  Am Heart J       Date:  1978-11       Impact factor: 4.749
View more
  13 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 4.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

5.  Conjugation pathways in liver disease.

Authors:  G M Pacifici; A Viani; M Franchi; S Santerini; A Temellini; L Giuliani; M Carrai
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

6.  Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states.

Authors:  I W Taylor; T Taylor; I James; G Doyle; G Dorf; A Darragh; L F Chasseaud
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Authors:  Julie Steelandt; Elodie Jean-Bart; Sylvain Goutelle; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

Review 8.  Drug-induced hepatic disorders. Incidence, management and avoidance.

Authors:  M Døssing; J Sonne
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

9.  Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction.

Authors:  M J Farthing; E M Alstead; S M Abrams; G Haug; A Johnston; R Hermann; G Niebch; P Ruus; K H Molz; P Turner
Journal:  Postgrad Med J       Date:  1994-05       Impact factor: 2.401

Review 10.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.